S1801: A randomized phase II trial of adjuvant versus neoadjuvant pembrolizumab (PEM) for melanoma.

被引：0
|
作者：
Patel, Sapna Pradyuman
Othus, Megan
Moon, James
Tetzlaff, Michael T.
Buchbinder, Elizabeth Iannotti
Sondak, Vernon K.
Lowe, Michael C.
Campos, Danae
Sharon, Elad
Korde, Larissa A.
Carson, William Edgar
Ribas, Antoni
Grossmann, Kenneth F.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[3] Southwest Oncol Grp, Stat Ctr, Seattle, WA USA
[4] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[6] Emory Univ, Dept Surg, Atlanta, GA USA
[7] SWOG Operatons Off, San Antonio, TX USA
[8] NCI, Bethesda, MD 20892 USA
[9] NCI, Clin Invest Branch, Bethesda, MD 20892 USA
[10] Ohio State Univ, Dept Surg, Comprehens Canc Ctr, Columbus, OH 43210 USA
[11] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA
[12] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS10090
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial
    Long, Georgina V.
    Carlino, Matteo S.
    Au-Yeung, George
    Spillane, Andrew J.
    Shannon, Kerwin F.
    Gyorki, David E.
    Hsiao, Edward
    Kapoor, Rony
    Thompson, Jake R.
    Batula, Iris
    Howle, Julie
    Ch'ng, Sydney
    Gonzalez, Maria
    Saw, Robyn P. M.
    Pennington, Thomas E.
    Lo, Serigne N.
    Scolyer, Richard A.
    Menzies, Alexander M.
    NATURE MEDICINE, 2024, 30 (09) : 2540 - 2548
  • [32] SWOG S1320: A randomized phase II trial of intermittent versus continuous dosing of dabrafenib and trametinib in BRAFV600E/k mutant melanoma.
    Algazi, Alain Patrick
    Othus, Megan
    Daud, Adil
    Mehnert, Janice M.
    Lao, Christopher D.
    Kudchadkar, Ragini Reiney
    Grossmann, Kenneth F.
    Lo, Roger
    Moon, James
    Kirkwood, John M.
    Ribas, Antoni
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] Phase II trial of extended-dosing temozolomide in patients with melanoma.
    Rietschel, P.
    Ejadi, S.
    Wolchok, J.
    Krown, S.
    Gerst, S.
    Jungbluth, A. A.
    Busam, K.
    Smith, K.
    Panageas, K.
    Chapman, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 463S - 463S
  • [34] Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial
    Yoon, Charles H.
    Ross, Merrick I.
    Gastman, Brian R.
    Luke, Jason J.
    Ascierto, Paolo A.
    Long, Georgina V.
    Rutkowski, Piotr
    Khattak, Muhammad
    Del Vecchio, Michele
    de la Cruz Merino, Luis
    Mackiewicz, Jacek
    Chiarion-Sileni, Vanna
    Schadendorf, Dirk
    Carlino, Matteo S.
    Zhao, Yujie
    Fukunaga-Kalabis, Mizuho
    Krepler, Clemens
    Eggermont, Alexander M. M.
    Gershenwald, Jeffrey E.
    Sondak, Vernon K.
    ANNALS OF SURGICAL ONCOLOGY, 2025, 32 (04) : 2756 - 2764
  • [35] ENCORE 601: A phase II study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with melanoma.
    Johnson, Melissa Lynne
    Gonzalez, Rene
    Opyrchal, Mateusz
    Gabrilovich, Dmitry
    Ordentlich, Peter
    Brouwer, Susan
    Sankoh, Serap
    Schmidt, Emmett V.
    Meyers, Michael L.
    Agarwala, Sanjiv S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [36] NeoPeLe: A phase II trial of neoadjuvant (NAT) pembrolizumab (Pembro) combined with lenvatinib (Lenva) in resectable stage III melanoma
    Long, G. V.
    Spillane, A. J.
    Pennington, T. E.
    Shannon, K. F.
    Stretch, J.
    Gonzalez, M.
    Saw, R. P. M.
    Lo, S. N.
    Scolyer, R. A.
    Menzies, A. M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S906 - S907
  • [37] Phase II trial of neoadjuvant temozolomide in resectable melanoma patients
    Shah, G. D.
    Socci, N. D.
    Gold, J. S.
    Wolchok, J. D.
    Carvajal, R. D.
    Panageas, K. S.
    Viale, A.
    Brady, M. S.
    Coit, D. G.
    Chapman, P. B.
    ANNALS OF ONCOLOGY, 2010, 21 (08) : 1718 - 1722
  • [38] Analysis of neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma using the SWOG S1801 event-free survival definition.
    De Barros E Silva, Milton Jose
    Tavares, Monique Celeste
    Lima, Joao Paulo S. N.
    Garcia, Daniel
    Molina, Andre
    Lobo, Matheus
    Lopes Pinto, Clovis Antonio
    De Paula, Rafaela Brito
    Rinck, Jose Augusto, Jr.
    Duprat Neto, Joao Pedreira
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] RANDOMIZED PHASE-II TRIAL OF TCNU VERSUS MITOZOLOMIDE IN MALIGNANT-MELANOMA
    SMYTH, JF
    GUNDERSEN, S
    RENARD, J
    PINEDO, HM
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (04): : 755 - 757
  • [40] Combination of radiomic and biomarker signatures as exploratory objective in a phase II trial with intratumoral BO-112 plus pembrolizumab for advanced melanoma.
    Marquez-Rodas, Ivan
    Dalle, Stephane
    Castanon, Eduardo
    Sanmamed, Miguel F.
    Arance, Ana Maria
    Cerezuela-Fuentes, Pablo
    Huertas, Roberto Martin
    Rodriguez-Moreno, Juan Francisco
    Gonzalez-Cao, Maria
    Munoz-Couselo, Eva
    Martin-Liberal, Juan
    Rodriguez-Abreu, Delvys
    Alberich-Bayarri, Angel
    Mayorga-Ruiz, Irene
    Vila, Miguel Angel Molina
    Roman, Ruth
    Chaney, Marya F.
    Lopez, Javier Sanchez
    Macia, Sonia
    Quintero, Marisol
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345